Method of destroying hyperproliferative cells by combined p53 and taxoid treatment
US6262032A · kind A · utility
3Cited by
5References
12Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 17, 1997 |
| Grant date | Jul 17, 2001 |
| Priority date | — |
| Expiry date | Jul 17, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A medicinal combination of one or more nucleic acids that at least partially inhibit oncogenic cell signalling pathways, and a therapeutic anticancer agent, for use simultaneous, separate or over a period of time to treat hyperproliferative diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.